These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2405043)

  • 1. Biological and neuropsychological characterization of physostigmine responders and nonresponders in Alzheimer's disease.
    Harrell LE; Jope RS; Falgout J; Callaway R; Avery C; Spiers M; Leli D; Morere D; Halsey JH
    J Am Geriatr Soc; 1990 Feb; 38(2):113-22. PubMed ID: 2405043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral physostigmine treatment for patients with presenile and senile dementia of the Alzheimer's type: a double-blind placebo-controlled trial.
    Jenike MA; Albert MS; Heller H; Gunther J; Goff D
    J Clin Psychiatry; 1990 Jan; 51(1):3-7. PubMed ID: 2403997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of oral physostigmine in Alzheimer's disease.
    Stern Y; Sano M; Mayeux R
    Ann Neurol; 1987 Sep; 22(3):306-10. PubMed ID: 3674795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physostigmine effects in Alzheimer's disease: relationship to dementia severity.
    Schwartz AS; Kohlstaedt EV
    Life Sci; 1986 Mar; 38(11):1021-8. PubMed ID: 3512944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of long-term physostigmine administration in Alzheimer's disease.
    Harrell LE; Callaway R; Morere D; Falgout J
    Neurology; 1990 Sep; 40(9):1350-4. PubMed ID: 2392216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic oral physostigmine without lecithin improves memory in Alzheimer's disease.
    Thal LJ; Masur DM; Blau AD; Fuld PA; Klauber MR
    J Am Geriatr Soc; 1989 Jan; 37(1):42-8. PubMed ID: 2642499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term administration of oral physostigmine in Alzheimer's disease.
    Stern Y; Sano M; Mayeux R
    Neurology; 1988 Dec; 38(12):1837-41. PubMed ID: 3057398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physostigmine and tetrahydroaminoacridine treatment of Alzheimer's disease.
    Gustafson L
    Acta Neurol Scand Suppl; 1993; 149(Rand):39-41. PubMed ID: 8128836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of physostigmine and lecithin on memory in Alzheimer disease.
    Peters BH; Levin HS
    Ann Neurol; 1979 Sep; 6(3):219-21. PubMed ID: 534419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No effect from double-blind trial of physostigmine and lecithin in Alzheimer disease.
    Wettstein A
    Ann Neurol; 1983 Feb; 13(2):210-2. PubMed ID: 6830183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of oral physostigmine in the treatment of Alzheimer disease.
    Sano M; Bell K; Marder K; Stricks L; Stern Y; Mayeux R
    Clin Neuropharmacol; 1993 Feb; 16(1):61-9. PubMed ID: 8422658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral physostigmine treatment of patients with Alzheimer's disease.
    Mohs RC; Davis BM; Johns CA; Mathé AA; Greenwald BS; Horvath TB; Davis KL
    Am J Psychiatry; 1985 Jan; 142(1):28-33. PubMed ID: 3881051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous physostigmine treatment of Alzheimer's disease evaluated by psychometric testing, regional cerebral blood flow (rCBF) measurement, and EEG.
    Gustafson L; Edvinsson L; Dahlgren N; Hagberg B; Risberg J; Rosén I; Fernö H
    Psychopharmacology (Berl); 1987; 93(1):31-5. PubMed ID: 3114812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group.
    Thal LJ; Schwartz G; Sano M; Weiner M; Knopman D; Harrell L; Bodenheimer S; Rossor M; Philpot M; Schor J; Goldberg A
    Neurology; 1996 Dec; 47(6):1389-95. PubMed ID: 8960716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of physostigmine on constructional and memory tasks in Alzheimer's disease.
    Muramoto O; Sugishita M; Sugita H; Toyokura Y
    Arch Neurol; 1979 Aug; 36(8):501-3. PubMed ID: 508162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine.
    Davis KL; Mohs RC
    Am J Psychiatry; 1982 Nov; 139(11):1421-4. PubMed ID: 6753611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical studies of the cholinergic deficit in Alzheimer's disease. II. Psychopharmacologic studies.
    Mohs RC; Davis BM; Greenwald BS; Mathé AA; Johns CA; Horvath TB; Davis KL
    J Am Geriatr Soc; 1985 Nov; 33(11):749-57. PubMed ID: 2865282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral physostigmine as treatment for primary degenerative dementia: a double-blind placebo-controlled inpatient trial.
    Jenike MA; Albert M; Baer L; Gunther J
    J Geriatr Psychiatry Neurol; 1990; 3(1):13-6. PubMed ID: 2189429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cortisol responses to cholinergic drugs in Alzheimer's disease.
    Kumar V; Smith RC; Sherman KA; Ashford W; Murphy J; Giacobini E; Colliver J
    Int J Clin Pharmacol Ther Toxicol; 1988 Oct; 26(10):471-6. PubMed ID: 3069749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of oral physostigmine in primary degenerative dementia. A double-blind study of response to different dose level.
    Beller SA; Overall JE; Swann AC
    Psychopharmacology (Berl); 1985; 87(2):147-51. PubMed ID: 3931138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.